Global Anti-Parkinson Drugs Market Report 2022 – Market Forecast, Trends And Strategies

20 May, 2022

The global anti-Parkinson’s drugs market size is expected to grow from $8.86 billion in 2021 to $9.56 billion in 2022 at a compound annual growth rate (CAGR) of 7.9%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global anti-Parkinson drugs market size is expected to reach $12.25 billion in 2026 at a CAGR of 6.4%.

What is the Global Anti-Parkinson Drugs Market?

The anti-Parkinson drugs market consists of sales of drugs used for treating Parkinson's disease (PD), generated by the establishments that manufacture these drugs. Parkinson's disease is a neurodegenerative disorder that affects predominately dopaminergic neurons in a specific area of the brain named substantia nigra and disturbs the movement of the body. People suffering from PD may experience tremor, bradykinesia, limb rigidity, gait, and balance problems.

Get a Sample of the global anti-Parkinson drugs market report

What drives the Global Anti-Parkinson Drugs Market?

The increasing geriatric population and surging cases of Parkinson's disease (PD) are projected to drive the demand for the anti-Parkinson drugs market. PD commonly occurs in people over the age of 60 years. According to the United Nations Department of Economic and Social Affairs, one in 11 people in the world was over the age of 65 in 2019 and this number is expected to increase to one in six people by the end of 2050. Furthermore, according to the Michael J. Fox Foundation for Parkinson’s Research’s statistics published in June 2019, over 1 million Americans live with PD. Degeneration of neurons in the geriatric population and the surge in cases of Parkinson’s disease is therefore driving the market growth.

Get the full global anti-Parkinson drugs industry report here

Global Anti-Parkinson Drugs Market Segments
The global anti-Parkinson drugs market is segmented:
By Drugs Class: Levodopa/Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-inhibitors, Anticholinergics, Others
By Route of Administration: Oral, Injection, Transdermal
By Distribution Channel: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies
By Geography: The regions covered in the anti-Parkinson drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Anti-Parkinson Drugs Global Market Report 2022 provides market size and growth forecasts for the global anti-Parkinson drugs market, global anti-Parkinson drugs market share, anti-Parkinson drugs market segments and geographies, anti-Parkinson drugs market competitive landscape including leading competitors’ revenues, profiles and market shares. The anti-Parkinson drugs market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.

Global Anti-Parkinson Drugs Industry Players include GlaxoSmithKline plc, Pfizer, Merck, Novartis, Roche, UCB S.A, Teva Pharmaceuticals, AbbVie Inc., Mylan, Boehringer Ingelheim, Orion Pharma, ACADIA Pharmaceuticals Inc, Sun Pharma, Wockhardt, Dr. Reddy’s, Intas, US WorldMeds, Zydus Cadila, Cipla, Strides, 1 A Pharma, Upsher-Smith, Lundbeck, Vertical Pharmaceuticals, LLC, Zambon Pharmaceuticals, M Somerset Pharmaceuticals Inc., and Wockhardt. Based on industry trends and company analysis, the report explains a number of strategies for companies in the market.